Targeting myeloid chemotaxis to improve clinical outcomes from radioligand therapy in advanced prostate cancer

The Defense Health Agency awarded $1,283,746 to the Institute of Cancer Research: Royal Cancer Hospital on September 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to target myeloid chemotaxis and improve clinical outcomes from radioligand therapy in advanced prostate cancer. Work will be performed in Great Britain, United Kingdom, with a period of performance through September 14, 2030. The Institute of Cancer Research: Royal Cancer Hospital, a United Kingdom-based nonprofit research organization, conducts hypothesis-driven biomedical and translational cancer research focused on oncology therapeutics and biomarker discovery targeting advanced cancers with military-relevant health priorities. This award supports basic, applied, and advanced biomedical research aligned with Defense Health Agency objectives to transform health care for Service Members and the American public through innovative and impactful research.